ST. PAUL, Minn., March 7, 2012 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), and EMD Serono, Inc., a leader in the U.S. biopharmaceutical market and subsidiary of Merck KGaA, Darmstadt, Germany, have entered into an agreement bringing the first outcomes-based rebate contract for a multiple sclerosis (MS) drug to Prime's CareCentered Contracting program. As an integrated PBM with its health plan clients, Prime is uniquely positioned to ensure members are taking effective prescription medications that truly improve their health by evaluating outcomes data throughout the entire length of the contract.
"With more than 57 percent of the direct health care costs to treat MS in the United States related to drug expenses, it is important to focus on medication adherence and cost effectiveness to ensure the greatest health benefit for each dollar spent," said Peter Wickersham, senior vice president of cost of care at Prime. "Our CareCentered Contract with EMD Serono goes beyond outcomes to do just that. It includes the total cost of care component, inclusive of medical and pharmacy costs and medication adherence."
The contract, which began January 1, stipulates that EMD Serono will pay rebates to Prime on the utilization of Rebif (interferon beta-1a) if patients who are on the drug have a higher overall total cost to their plans than patients on a different MS drug, or if the medication adherence rate remains above a specified level. Prime will evaluate data pertaining to the health outcomes and medication adherence of patients a number of times throughout the contract in order to determine the total cost of care, including medical and pharmacy costs.
"Enabling excellent patient and payer outcomes is more important than ever for biopharmaceutical manufacturers in today's health care environment," said Mike Dezelan, senior vice president of managed markets at EMD Serono. "Our innovative contract with Prim
|SOURCE Prime Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved